A randomized, open-label study comparing the effect of Xeloda [capecitabine] plus intravenous Eloxatin [oxaliplatin] (Xelox) with the standard combination treatment regimen of 5-fluorouracil, folinic acid, and Eloxatin on tumor response in treatment-naive patients with metastatic colorectal cancer

Trial Profile

A randomized, open-label study comparing the effect of Xeloda [capecitabine] plus intravenous Eloxatin [oxaliplatin] (Xelox) with the standard combination treatment regimen of 5-fluorouracil, folinic acid, and Eloxatin on tumor response in treatment-naive patients with metastatic colorectal cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2011

At a glance

  • Drugs Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Feb 2011 Results published in the International Journal of Cancer.
    • 10 Jan 2008 Status changed from in progress to completed.
    • 09 Feb 2007 ASCO Gastrointestinal Cancer Symposium 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top